An Open-label PET Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739
Latest Information Update: 04 Nov 2021
At a glance
- Drugs JNJ-55308942 (Primary) ; 18F-JNJ-64413739
- Indications Epilepsy; Inflammation; Inflammatory bowel diseases; Mood disorders
- Focus Pharmacokinetics
- Sponsors Janssen-Cilag
- 18 Jan 2019 Status changed from recruiting to completed.
- 27 Sep 2018 Planned primary completion date changed from 15 Aug 2018 to 28 Oct 2018.
- 27 Jul 2018 Planned End Date changed from 15 Aug 2018 to 28 Oct 2018.